Key Points
-
Recently, it has been demonstrated that cell senescence in culture is not only induced by an intrinsic cell division counter mechanism (replicative senescence), but can also be induced by extrinsic factors such as culture conditions (premature senescence). The only known cell division counter is telomere shortening.
-
It has been proposed that replicative senescence suppresses tumorigenesis in vivo, as >90% tumours express telomerase at high levels and maintain telomere lengths. This is essential for their continued proliferation.
-
The increased cancer phenotype of the telomerase knockout mouse has shown that the role of telomere shortening in human cancer is difficult to predict. Depending on genetic context, telomere shortening can either promote or protect against tumorigenesis in mice. It is difficult to extrapolate these results to humans due to differing telomerase expression patterns and different telomere lengths.
-
Telomerase expression in human cells appears to correlate with proliferative requirements. These expression patterns may reflect a balance between different aspects of telomerase function: maintenance of telomere length and thus proliferative capacity; maintenance of genetic integrity; and a possible direct proliferative role.
-
Premature senescence, for example induced by oncogenic RAS or by suboptimal conditions equivalent to 'culture shock', may also operate as a tumour-suppressive mechanism.
-
Telomere shortening and thus increased genetic instability may account for the increased incidence of cancer as we age. An accumulation of senescent cells may also create environments that are more sustainable for tumour growth.
-
Both premature and replicative senescence could contribute to the progressive decline in bodily function associated with ageing. An accumulation of senescent cells may hinder normal function, decrease regenerative capacity and increase genetic damage.
-
The elevated expression of telomerase in almost all tumours may provide a diagnostic and prognostic tool for cancer. Moreover, as tumour cells require telomerase expression for continued proliferation, inhibitors of telomerase activity may provide effective cancer therapies.
Abstract
Historically, the senescent state has been associated with, and was named after, the cell-cycle arrest that occurs after cells have undergone an intrinsically defined number of divisions in vitro. More recently, however, it has been shown that extrinsic factors, including those encountered in normal tissue-culture environments, can prematurely induce an indistinguishable senescent phenotype. In this review, we discuss the pathways of cell senescence, the mechanisms involved and the role that these pathways have in regulating the initiation and progression of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hayflick, L. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).
Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636 (1965).
Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
Artandi, S. E. & DePinho, R. A. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr. Opin. Genet. Dev. 10, 39–46 (2000).
Hara, E., Tsurui, H., Shinozaki, A., Nakada, S. & Oda, K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Commun. 179, 528–534 (1991).
Shay, J. W., Pereira-Smith, O. M. & Wright, W. E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res. 196, 33–39 (1991).
Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458–460 (1990).
Bodnar, A. G. et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349–352 (1998).
Vaziri, H. & Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279–282 (1998).References 8 and 9 show how telomerase expression immortalizes human cells.
Kiyono, T. et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84–88 (1998).Human epithelial cells seem to have, in addition to telomere shortening, a second checkpoint that determines replicative lifespan.
Di Leonardo, A., Linke, S. P., Clarkin, K. & Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540–2551 (1994).
Robles, S. J. & Adami, G. R. Agents that cause DNA double strand breaks lead to p16INK4A enrichment and the premature senescence of normal fibroblasts. Oncogene 16, 1113–1123 (1998).
Chen, Q. & Ames, B. N. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc. Natl Acad. Sci. USA 91, 4130–4134 (1994).
Finkel, T. & Holbrook, N. J. Oxidants, oxidative stress and the biology of ageing. Nature 408, 239–247 (2000).
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4A. Cell 88, 593–602 (1997).Oncogenic RAS expression in normal cells triggers premature senescence.
Sherr, C. J. & DePinho, R. A. Cellular senescence: mitotic clock or culture shock? Cell 102, 407–410 (2000).
Wright, W. E. & Shay, J. W. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nature Med. 6, 849–851 (2000).
Mathon, N. F., Malcolm, D. S., Harrisingh, M. C., Cheng, L. & Lloyd, A. C. Lack of replicative senescence in normal rodent glia. Science 291, 872–875 (2001).
Tang, D. G., Tokumoto, Y. M., Apperly, J. A., Lloyd, A. C. & Raff, M. C. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science 291, 868–871 (2001).
Shay, J. W. & Wright, W. E. Aging: when do telomeres matter? Science 291, 839–840 (2001).
Ramirez, R. D. et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev. 15, 398–403 (2001).References 18, 19 and 21 show that culture conditions, rather than an intrinsic clock, limit the proliferative lifespan of many cell types.
Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011–2015 (1994).
Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A. & Reddel, R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Med. 3, 1271–1274 (1997).
Hastie, N. D. et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346, 866–868 (1990).
Sommerfeld, H. J. et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 56, 218–222 (1996).
Hahn, W. C. et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Med. 5, 1164–1170 (1999).Shows that cancer cells need to maintain telomerase activity.
Hahn, W. C. et al. Creation of human tumour cells with defined genetic elements. Nature 400, 464–468 (1999).How many genetic changes to transform a normal human cell?
Blasco, M. A. et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25–34 (1997).Mouse cells lacking telomerase senesce at the same rate, are immortalized and are as transformable as wild-type cells.
Artandi, S. E. & DePinho, R. A. Mice without telomerase: what can they teach us about human cancer? Nature Med. 6, 852–855 (2000).
Lee, H. W. et al. Essential role of mouse telomerase in highly proliferative organs. Nature 392, 569–574 (1998).
Rudolph, K. L. et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96, 701–712 (1999).Documents the unexpected finding that telomerase-deficient mice have an increased predisposition to cancer.
Hande, M. P., Samper, E., Lansdorp, P. & Blasco, M. A. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J. Cell Biol. 144, 589–601 (1999).
Niida, H. et al. Severe growth defect in mouse cells lacking the telomerase RNA component. Nature Genet. 19, 203–206 (1998).
Counter, C. M. et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921–1929 (1992).
Hackett, J. A., Feldser, D. M. & Greider, C. W. Telomere dysfunction increases mutation rate and genomic instability. Cell 106, 275–286 (2001).
Chin, L. et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527–538 (1999).
Artandi, S. E. et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406, 641–645 (2000).
Serrano, M. et al. Role of the INK4A locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996).
Greenberg, R. A. et al. Short dysfunctional telomeres impair tumorigenesis in the INK4A(δ2/3) cancer-prone mouse. Cell 97, 515–525 (1999).
Gonzalez-Suarez, E., Samper, E., Flores, J. M. & Blasco, M. A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nature Genet. 26, 114–117 (2000).
Rudolph, K. L., Millard, M., Bosenberg, M. W. & DePinho, R. A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nature Genet. 28, 155–159 (2001).References 39–41 show that replicative senescence can protect against tumorigenesis when the frequency of tumour initiation is increased.
Su, L. K. et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668–670 (1992).
Hart, R. W. & Setlow, R. B. Correlation between deoxyribonucleic acid excision-repair and life-span in a number of mammalian species. Proc. Natl Acad. Sci. USA 71, 2169–2173 (1974).
Kolquist, K. A. et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nature Genet. 19, 182–186 (1998).
Harle-Bachor, C. & Boukamp, P. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc. Natl Acad. Sci. USA 93, 6476–6481 (1996).
Gonzalez-Suarez, E. et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20, 2619–2630 (2001).Indicates that high levels of telomerase might have an additional proliferative effect.
Oh, H. et al. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc. Natl Acad. Sci. USA 98, 10308–10313 (2001).
Prowse, K. R. & Greider, C. W. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc. Natl Acad. Sci. USA 92, 4818–4822 (1995).
Greenberg, R. A., Allsopp, R. C., Chin, L., Morin, G. B. & DePinho, R. A. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 16, 1723–1730 (1998).
Blasco, M. A., Rizen, M., Greider, C. W. & Hanahan, D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nature Genet. 12, 200–204 (1996).
Chadeneau, C., Siegel, P., Harley, C. B., Muller, W. J. & Bacchetti, S. Telomerase activity in normal and malignant murine tissues. Oncogene 11, 893–898 (1995).
Vaziri, H. et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl Acad. Sci. USA 91, 9857–9860 (1994).
Vaziri, H. et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am. J. Hum. Genet. 52, 661–667 (1993).
Zhang, A. et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res. 60, 6230–6235 (2000).
Greenberg, R. A. et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18, 1219–1226 (1999).
Wu, K. J. et al. Direct activation of TERT transcription by c-MYC. Nature Genet. 21, 220–224 (1999).
Wang, J., Xie, L. Y., Allan, S., Beach, D. & Hannon, G. J. Myc activates telomerase. Genes Dev. 12, 1769–1774 (1998).
Oh, S. T., Kyo, S. & Laimins, L. A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 75, 5559–5566 (2001).
Klingelhutz, A. J., Foster, S. A. & McDougall, J. K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380, 79–82 (1996).
Weinberg, R. A. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 49, 3713–3721 (1989).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Lloyd, A. C. Ras versus cyclin-dependent kinase inhibitors. Curr. Opin. Genet. Dev. 8, 43–48 (1998).
Adams, J. M. & Cory, S. Transgenic models of tumor development. Science 254, 1161–1167 (1991).
Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111–1116 (2001).
Lloyd, A. C. et al. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 11, 663–677 (1997).
Roper, E., Weinberg, W., Watt, F. M. & Land, H. p19ARF-independent induction of p53 and cell cycle arrest by Raf in murine keratinocytes. EMBO Rep. 2, 145–150 (2001).
Lin, A. W. & Lowe, S. W. Oncogenic ras activates the ARF–p53 pathway to suppress epithelial cell transformation. Proc. Natl Acad. Sci. USA 98, 5025–5030 (2001).
Lemoine, N. R. et al. Partial transformation of human thyroid epithelial cells by mutant H-ras oncogene. Oncogene 5, 1833–1837 (1990).
Foster, S. A., Wong, D. J., Barrett, M. T. & Galloway, D. A. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell Biol. 18, 1793–1801 (1998).
Romanov, S. R. et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633–637 (2001).
Hui, R. et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin. Cancer Res. 6, 2777–2787 (2000).
Johnson, F. B., Sinclair, D. A. & Guarente, L. Molecular biology of aging. Cell 96, 291–302 (1999).
West, M. D., Pereira-Smith, O. M. & Smith, J. R. Replicative senescence of human skin fibroblasts correlates with a loss of regulation and overexpression of collagenase activity. Exp. Cell Res. 184, 138–147 (1989).
Ames, B. N., Shigenaga, M. K. & Hagen, T. M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl Acad. Sci. USA 90, 7915–7922 (1993).
DePinho, R. A. The age of cancer. Nature 408, 248–254 (2000).
Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002–5011 (1999).
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y. & Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072–12077 (2001).
Foster, B. A., Coffey, H. A., Morin, M. J. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510 (1999).
Bullock, A. N. & Fersht, A. R. Rescuing the function of mutant p53. Nature Rev. Cancer 1, 68–76 (2001).
Collins, K. Mammalian telomeres and telomerase. Curr. Opin. Cell Biol. 12, 378–383 (2000).
Smogorzewska, A. et al. Control of human telomere length by TRF1 and TRF2. Mol. Cell Biol. 20, 1659–1668 (2000).
Griffith, J. D. et al. Mammalian telomeres end in a large duplex loop. Cell 97, 503–514 (1999).
Greider, C. W. Telomeres do D-loop–T-loop. Cell 97, 419–422 (1999).
Blackburn, E. H. Telomere states and cell fates. Nature 408, 53–56 (2000).
Hemann, M. T., Strong, M. A., Hao, L. Y. & Greider, C. W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107, 67–77 (2001).
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S. & de Lange, T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283, 1321–1325 (1999).
van Steensel, B., Smogorzewska, A. & de Lange, T. TRF2 protects human telomeres from end-to-end fusions. Cell 92, 401–413 (1998).
Herrera, E. et al. Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J. 18, 2950–2960 (1999).
Liu, Y. et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr. Biol. 10, 1459–1462 (2000).
Nikaido, R. et al. Presence of telomeric G-strand tails in the telomerase catalytic subunit Tert knockout mice. Genes Cells 4, 563–572 (1999).
Herrera, E., Martinez, A. C. & Blasco, M. A. Impaired germinal center reaction in mice with short telomeres. EMBO J. 19, 472–481 (2000).
Chang, S., Khoo, C. & DePinho, R. A. Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. Semin. Cancer Biol. 11, 227–239 (2001).
Blasco, M. A., Funk, W., Villeponteau, B. & Greider, C. W. Functional characterization and developmental regulation of mouse telomerase RNA. Science 269, 1267–1270 (1995).
Martin-Rivera, L., Herrera, E., Albar, J. P. & Blasco, M. A. Expression of mouse telomerase catalytic subunit in embryos and adult tissues. Proc. Natl Acad. Sci. USA 95, 10471–10476 (1998).
Brien, T. P. et al. Telomerase activity in benign endometrium and endometrial carcinoma. Cancer Res. 57, 2760–2764 (1997).
Bodnar, A. G., Kim, N. W., Effros, R. B. & Chiu, C. P. P. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 228, 58–64 (1996).
Holt, S. E., Wright, W. E. & Shay, J. W. Regulation of telomerase activity in immortal cell lines. Mol. Cell Biol. 16, 2932–2939 (1996).
Sharma, H. W. et al. Differentiation of immortal cells inhibits telomerase activity. Proc. Natl Acad. Sci. USA 92, 12343–12346 (1995).
Schneider, E. L. & Mitsui, Y. The relationship between in vitro cellular aging and in vivo human age. Proc. Natl Acad. Sci. USA 73, 3584–3588 (1976).
Allsopp, R. C. et al. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl Acad. Sci. USA 89, 10114–10118 (1992).
Cristofalo, V. J., Allen, R. G., Pignolo, R. J., Martin, B. G. & Beck, J. C. Relationship between donor age and the replicative lifespan of human cells in culture: a reevaluation. Proc. Natl Acad. Sci. USA 95, 10614–10619 (1998).
Kipling, D. & Faragher, R. G. Telomeres: ageing hard or hardly ageing? Nature 398, 191, 193 (1999).
Klapper, W., Parwaresch, R. & Krupp, G. Telomere biology in human aging and aging syndromes. Mech. Ageing Dev. 122, 695–712 (2001).
Marciniak, R. A. & Johnson, F. B. & Guarente, L. Dyskeratosis congenita, telomeres and human ageing. Trends Genet. 16, 193–195 (2000).
Mitchell, J. R., Wood, E. & Collins, K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402, 551–555 (1999).
Vulliamy, T. et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413, 432–435 (2001).
Ito, H. et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin. Cancer Res. 4, 2807–2810 (1998).
Takakura, M., Kyo, S., Kanaya, T., Tanaka, M. & Inoue, M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res. 58, 1558–1561 (1998).
Shammas, M. A., Simmons, C. G., Corey, D. R. & Shmookler Reis, R. J. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene 18, 6191–6200 (1999).
Hayakawa, N. et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 38, 11501–11507 (1999).
Hamilton, S. E., Simmons, C. G., Kathiriya, I. S. & Corey, D. R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6, 343–351 (1999).
Minev, B. et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl Acad. Sci. USA 97, 4796–4801 (2000).
Acknowledgements
We thank M. Raff and A. Hall for critical reading of the manuscript. A.C.L. is a Cancer Research Campaign Senior Cancer Research Fellow. N. F. M. is funded by the Medical Research Council graduate programme.
Author information
Authors and Affiliations
Corresponding author
Glossary
- SCHWANN CELL
-
Glial cell of the peripheral nervous system.
- OLIGODENDROCYTE PRECURSOR CELL
-
Glial cell precursor of the central nervous system.
- ALT
-
(Alternative lengthening of telomeres). A recombination-based mechansim that allows telomere length maintenance in the absence of telomerase activity.
- DOMINANT NEGATIVE
-
A defective protein that inhibits wild-type function by retaining interaction capabilities that result in distortion or competition with normal proteins.
- SV40 LARGE T ANTIGEN
-
A large multifunctional protein that is encoded by the Simian virus 40 (SV40). SV40 large T can bind and inhibit functions of p53- and RB-family members.
- MULTICENTRIC CHROMOSOMES
-
Chromosomes with more than one centromere.
- CDKN2A
-
This locus, which is commonly mutated in cancer, encodes two transcripts with overlapping reading frames — Ink4a and Arf. Both protein products are involved in negative regulation of the cell cycle.
- INK4A
-
A 16-kDa cyclin-dependent kinase inhibitor that is expressed from the Cdkn4a locus. It acts on cyclinD–CDK4/6 activity to inhibit cell-cycle progression.
- ARF
-
A 19-kDa protein (14 kDa in humans) that is expressed from the Cdkn2a locus in response to oncogenic stimuli. It functions by stabilizing p53.
- FAMILIAL ADENOMATOUS POLYPOSIS
-
Genetic disorder that is characterized by an increased predisposition to colorectal cancer, associated with germ-line mutations of the APC gene.
- CYCLIN-DEPENDENT KINASE INHIBITORS
-
(CDKIs). Proteins that inhibit cell-cycle progression by binding to and inhibiting cyclin-dependent kinases.
Rights and permissions
About this article
Cite this article
Mathon, N., Lloyd, A. Cell senescence and cancer. Nat Rev Cancer 1, 203–213 (2001). https://doi.org/10.1038/35106045
Issue Date:
DOI: https://doi.org/10.1038/35106045